PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23085230-0	2012	5-Fluorocytosine combined with Fcy-hEGF fusion protein targets EGFR-expressing cancer cells.	Flucytosine	0-16	epidermal growth factor receptor	Homo sapiens	63-67	
33672989-2	2021	Fcy-hEGF fusion protein, composed of yeast cytosine deaminase (Fcy) and human EGF (hEGF), is capable of binding to EGFR and enzymatically convert 5-fluorocytosine (5-FC) to 1000-fold toxic 5-fluorocuracil (5-FU), thereby inhibiting the growth of EGFR-expressing tumor cells.	Flucytosine	146-162	epidermal growth factor receptor	Homo sapiens	246-250	
33672989-2	2021	Fcy-hEGF fusion protein, composed of yeast cytosine deaminase (Fcy) and human EGF (hEGF), is capable of binding to EGFR and enzymatically convert 5-fluorocytosine (5-FC) to 1000-fold toxic 5-fluorocuracil (5-FU), thereby inhibiting the growth of EGFR-expressing tumor cells.	Flucytosine	164-168	epidermal growth factor receptor	Homo sapiens	246-250	
31840981-2	2020	Here, a fusion protein was designed with both an antiepidermal growth factor receptor (EGFR) affibody and the prodrug enzyme cytosine deaminase, which can convert prodrug 5-fluorocytosine to the anticancer drug 5-fluorouracil.	Flucytosine	171-187	epidermal growth factor receptor	Homo sapiens	87-91	
23085230-6	2012	Here, we adopted a prodrug system that uses 5-fluorocytosine (5-FC) and human EGF (hEGF) fused with yeast cytosine deaminase (Fcy) to target EGFR-overexpressing cancer cells and to convert 5-FC to a significantly more toxic chemotherapeutic, 5-fluorouracil (5-FU).	Flucytosine	44-60	epidermal growth factor receptor	Homo sapiens	141-145	
23085230-6	2012	Here, we adopted a prodrug system that uses 5-fluorocytosine (5-FC) and human EGF (hEGF) fused with yeast cytosine deaminase (Fcy) to target EGFR-overexpressing cancer cells and to convert 5-FC to a significantly more toxic chemotherapeutic, 5-fluorouracil (5-FU).	Flucytosine	189-193	epidermal growth factor receptor	Homo sapiens	141-145